Last reviewed · How we verify
ACT01
ACT01 is a small molecule that targets the S1P receptor.
ACT01 is a small molecule that targets the S1P receptor. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | ACT01 |
|---|---|
| Sponsor | Promius Pharma, LLC |
| Drug class | S1P receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Multiple Sclerosis |
| Phase | Phase 2 |
Mechanism of action
ACT01 works by selectively modulating the sphingosine-1-phosphate (S1P) receptor, which plays a crucial role in the regulation of immune cell trafficking and function.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
- Infections
Key clinical trials
- "Turkish Validation and Reliability Study of the Brompton Breathing Pattern Assessment Tool in Asthma Patients"
- Automated Inhaler Monitoring for Asthma Medication Usage (NA)
- Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation (NA)
- Remission in Adults With Mild-to-moderate Asthma in Thailand
- Remission in Adults With Severe Asthma in Thailand
- The Effect of Asthma Flare-up Clinic After Exacerbation (NA)
- Impact of COVID19 on Asthma Patients in Spain
- The Effect of Thyme Oil in Asthmatic Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACT01 CI brief — competitive landscape report
- ACT01 updates RSS · CI watch RSS
- Promius Pharma, LLC portfolio CI